What is Fujian Cosunter Pharmaceutical Co., Ltd.'s (300436.SZ) StockRank?

MoatMap's StockRank for Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ) is 13/100, with a Strong Sell signal. This is a composite score combining Quality (27), Value (20), and Momentum (41) factor ranks across MoatMap's 20,000+ stock universe.

Does Fujian Cosunter Pharmaceutical Co., Ltd. have an economic moat?

Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ) has a Quality factor score of 27/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Fujian Cosunter Pharmaceutical Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ) is Strong Sell, based on a StockRank of 13/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Fujian Cosunter Pharmaceutical Co., Ltd. in?

Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

300436.SZ

Strong Sell

Fujian Cosunter Pharmaceutical Co., Ltd. · Healthcare · China · $2.2B · Avg Vol: $91M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-70.9%

D/E

1.5x

Dividend %

—

COMPANY DESCRIPTION

Fujian Cosunter Pharmaceutical Co., Ltd. specializes in the research, development, and manufacture of nucleoside antiviral drugs, with a primary focus on hepatitis B treatments. The company holds a leading market share in China's domestic anti-HBV drug sector. Its competitive advantage is driven by a robust pipeline of generic and innovative antiviral therapies.

FINANCIAL SUMMARY (CNY)

Year	2022	2023	2024	2025	CAGR	TTM
Revenue	385.8M	422.7M	441.5M	416.4M	2.6%	417.9M
EPS (CNY)	-0.80	-2.19	-0.98	-1.37	—	-1.36
Shares	159.3M	159.3M	159.3M	159.3M	0.0%	159.3M
Debt	311.5M	459.3M	442.6M	456.0M	13.5%	487.8M
Equity	928.5M	516.5M	360.2M	277.5M	-33.1%	—
Op CF	-119.7M	-174.6M	20.7M	-35.1M	—	-42.7M
Inv CF	-197.2M	-207.4M	-45.8M	-62.1M	—	—
Fin CF	162.5M	349.7M	-34.5M	159.9M	—	—

Loading 1Y...

PRICE (1Y)-0.5%

SMA 50SMA 200

$14.14

RSI (14)

47.1

52W High

$28.11

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

-21.2%30.0

ROE

-70.9%14.0

GP/Assets

16.4%38.5

Op. Margin

-17.5%26.6

FCF/Assets

-6.8%33.7

Piotroski

431.8

Int. Cover

-6.0x27.5

D/E Ratio

1.54x8.6

Current Ratio

1.02x11.7

Value

P/E (TTM)

—N/A

EV/EBITDA

-367.0x25.0

P/FCF

—N/A

P/B

60.1x1.6

P/S

36.2x11.9

Div Yield

—N/A

Momentum

52W High %

50%23.0

RS 6M

—N/A

SMA 50/200

0.93x43.5

EPS Rev 4W

+1.2%55.5

EPS Rev 12W

+1.3%66.6

EPS Improve

+151%83.4

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$2.2B

P/E (Forward)

135.6x

Gross Margin

54.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 300436.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
300436.SZ	Fujian Cosunter Pharmaceutical Co., Ltd.(you)	$2.2B	13	Strong Sell
000766.SZ	Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd	$2.3B	8	Strong Sell
688321.SS	Shenzhen Chipscreen Biosciences Co., Ltd.	$1.7B	17	Strong Sell
688185.SS	CanSino Biologics Inc.	$2.6B	19	Strong Sell
000534.SZ	Wedge Industrial Co.,Ltd.	$1.8B	20	Strong Sell
301263.SZ	Guangdong Taienkang Pharmaceutical Co., Ltd.	$1.4B	8	Strong Sell
688192.SS	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	$4.2B	13	Strong Sell
688221.SS	Frontier Biotechnologies Inc.	$1.1B	12	Strong Sell
688176.SS	Jiangsu Yahong Meditech Co., Ltd.	$1.0B	13	Strong Sell
300723.SZ	ApicHope Pharmaceutical Group Co., Ltd.	$2.4B	28	Sell

Peer medians: ROE 4.5% · P/E 29.0x · Gross margin 52.6%

Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ): Stock Score Summary

Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ) has a MoatMap StockRank of 13/100 based on Quality (27/100), Value (20/100), and Momentum (41/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$14.14
Market Cap	$2.2B
P/E (Forward)	135.57
Price/Book	60.06
Return on Equity	-70.9%
Return on Invested Capital	-21.2%
Debt/Equity	1.54x
Gross Margin	54.2%
Operating Margin	-17.5%
Revenue Growth	0.9%
Free Cash Flow	$-14M

Fujian Cosunter Pharmaceutical Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Fujian Cosunter Pharmaceutical Co., Ltd.’s (300436.SZ) StockRank?: MoatMap’s StockRank for Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ) is 13/100, with a Strong Sell signal. It is a composite of Quality (27), Value (20), and Momentum (41) factor ranks across MoatMap’s 20,000+ stock universe.
Does Fujian Cosunter Pharmaceutical Co., Ltd. have an economic moat?: Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ) has a Quality factor score of 27/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Fujian Cosunter Pharmaceutical Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ) is Strong Sell, based on a StockRank of 13/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Fujian Cosunter Pharmaceutical Co., Ltd. in?: Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).